Growth Metrics

Bristol Myers Squibb (BMYMP) Long-Term Deferred Tax (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Long-Term Deferred Tax for 17 consecutive years, with $5.4 billion as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 26.96% to $5.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 billion through Dec 2025, up 26.96% year-over-year, with the annual reading at $5.4 billion for FY2025, 26.96% up from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $5.4 billion at Bristol Myers Squibb, up from $5.0 billion in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $5.4 billion in Q4 2025, with the low at $650.0 million in Q2 2021.
  • Average Long-Term Deferred Tax over 5 years is $2.5 billion, with a median of $1.5 billion recorded in 2023.
  • The sharpest move saw Long-Term Deferred Tax crashed 40.26% in 2021, then soared 138.38% in 2024.
  • Over 5 years, Long-Term Deferred Tax stood at $1.4 billion in 2021, then dropped by 6.6% to $1.3 billion in 2022, then skyrocketed by 105.95% to $2.8 billion in 2023, then skyrocketed by 53.03% to $4.2 billion in 2024, then grew by 26.96% to $5.4 billion in 2025.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $5.4 billion, $5.0 billion, and $4.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.